1 ytokine with potent megakaryocytopoietic and
thrombopoietic activities in vivo.
2 We conclude that rhIL-11 has
thrombopoietic activity at all doses studied, is well to
3 e-daily, oral TpoR agonist with demonstrated
thrombopoietic activity in human subjects, encouraging f
4 Interleukin (IL)-11 is a cytokine with
thrombopoietic activity that has been shown to increase
5 everal cell-based assays designed to measure
thrombopoietic activity.
6 In this first study of a
thrombopoietic agent in children, patients with ITP of >
7 s with a platelet response to Eltrombopag, a
thrombopoietic agent, but none responding to an anti-Fcg
8 We asked whether eltrombopag, a
thrombopoietic agent, would increase platelet counts, im
9 summarizes the history of the development of
thrombopoietic agents and discusses their potential use
10 in ITP patients with low platelet counts on
thrombopoietic agents and positively correlated with T-c
11 was cloned and characterized and therapeutic
thrombopoietic agents developed.
12 Nonresponders to
thrombopoietic agents had increased megakaryocytes but n
13 The second generation of
thrombopoietic agents has been shown to correct thromboc
14 A new generation of
thrombopoietic agents have had preliminary success in th
15 In conclusion, our findings suggest that
thrombopoietic agents in patients with ITP have profound
16 ese data further encourage short-term use of
thrombopoietic agents in patients with MYH9-RDs; however
17 Now, a second generation of synthetic
thrombopoietic agents including AMG 531 and eltrombopag
18 Clinical trials using
thrombopoietic agents to stimulate platelet production h
19 The initial
thrombopoietic agents were recombinant and pegylated hum
20 hanisms (e.g. anti-CD20 monoclonal antibody,
thrombopoietic agents) have shown promising results in r
21 et counts were elevated after treatment with
thrombopoietic agents, the frequency of CD19(+)CD24(hi)C
22 ding 3 who had not persistently responded to
thrombopoietic agents.
23 ients were free of blood product support and
thrombopoietic agonists.
24 ileukemic agents by virtue of their combined
thrombopoietic and antileukemic effects.
25 genitor (GMP) compartments at the expense of
thrombopoietic and red cell precursors.
26 Identification of a progenitor with enhanced
thrombopoietic capacity would be useful to decipher thes
27 In addition,
thrombopoietic cells derived from TSP-DKO mice were more
28 Thus, TSP-deficient
thrombopoietic cells function as proangiogenic agents, a
29 Thrombopoietic cells may differentially promote or inhib
30 es of thrombospondins 1 and 2 and that these
thrombopoietic cells play key roles in controlling blood
31 ants controlling the angiogenic phenotype of
thrombopoietic cells remain unknown.
32 The proangiogenic activity of TSP-DKO
thrombopoietic cells was mediated through activation of
33 To determine the relationship of endogenous
thrombopoietic cytokine levels and circulating platelet
34 Interleukin-11 (IL-11) is a
thrombopoietic cytokine that attenuates postchemotherapy
35 investigated the mechanism of action of the
thrombopoietic cytokine, recombinant human interleukin-1
36 rine circuit wherein increased production of
thrombopoietic cytokines in tumor and host tissue leads
37 PO and IL-11, therefore, appear to be active
thrombopoietic cytokines regulating, in part, megakaryoc
38 The availability of various
thrombopoietic cytokines, in particular thrombopoietin (
39 ive megakaryopoiesis in vitro, corrected the
thrombopoietic defect, defects in thrombus formation and
40 ith mice transgenic for Pf4-Cre-recombinase (
thrombopoietic deletion) or Cd11b-Cre-recombinase (myelo
41 The
thrombopoietic efficacy of recombinant forms of c-mpl li
42 The
thrombopoietic environment of the neonate is established
43 to peripheral destruction from those due to
thrombopoietic failure.
44 Interleukin-11 (IL-11) is a unique
thrombopoietic growth factor which causes proliferation
45 tics Institute, Inc, Cambridge, MA), a novel
thrombopoietic growth factor, in reducing the need for p
46 Although development of first-generation
thrombopoietic growth factors (recombinant human thrombo
47 One or more second-generation
thrombopoietic growth factors should soon be clinically
48 All second-generation
thrombopoietic growth factors stimulate growth of TPO-de
49 EG-rHuMGDF, nonimmunogenic second-generation
thrombopoietic growth factors with unique pharmacologic
50 maintenance of erythrocyte levels following
thrombopoietic insult.
51 strate that in mice deficient for NF-E2 (the
thrombopoietic master regulator), the absence of membran
52 bocytopenias frequently shed light on normal
thrombopoietic mechanisms.
53 nhibitor expands platelet recovery in stress
thrombopoietic models with no adverse effects.
54 series of mutations in exon 12 of JAK2, the
thrombopoietic receptor gene MPL, and in the gene encodi
55 We demonstrate that
thrombopoietic recovery following myelosuppression was s
56 owever, a comprehensive kinetic study of the
thrombopoietic response to a single injection of recombi
57 The effects of
thrombopoietic stimulation on megakaryocytopoiesis, plat
58 genase 1 and thromboxane A synthase 1) and a
thrombopoietic transcription factor (Nf-e2).
59 ic ITP that may be restored in responders to
thrombopoietic treatment.